Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma

　　Binimetinib is a selective MEK1/2 inhibitor used mainly in combination with the BRAF inhibitor encorafenib rather than as monotherapy.BRAF V600E or V600K mutations cause constitutive activation of the RAS‑RAF‑MEK‑ERK pathway;encorafenib blocks mutant BRAF upstream and binimetinib blocks MEK downstream,producing vertical pathway inhibition and reducing feedback reactivation that often limits single‑agent BRAF inhibition.

　　The combination is indicated for unresectable or metastatic melanoma confirmed to carry BRAF V600E or V600K by an appropriate assay.It can produce relatively rapid tumor shrinkage,which is valuable for symptomatic disease or high tumor burden.Assessment should not rely only on diameter reduction;progression‑free survival,duration of response,overall survival and sites of metastasis should be considered together.

　　Common issues include fatigue,nausea,diarrhea,rash,elevated creatine kinase,ocular changes and reduced left ventricular function;baseline and periodic imaging,laboratory and ophthalmologic checks are needed.Some patients develop resistance over time through MAPK reactivation or alternative pathways,so regular follow‑up is required even after initial remission,and the oncology team should modify therapy on documented progression.